<!-- KLOW Research: No Study of the Blend, Five Component Papers | https://klowpens.com/klow-research/ -->

Guide · The literature

# No study of the _blend._

**There is no published study of this four-peptide pen or vial as one product.** The five papers below are the seller’s own short reading list. Each one was opened. Each one is about a single component, or about thymosin beta-4 rather than the fragment named on the KLOW certificate. None of them is a study of KLOW.

By the klowpens.com Editorial Team · Last reviewed November 18, 2026 · 5 papers

## The _gap._

A paper about one peptide is not a paper about four peptides in a pen.

Palm Beach Vitality’s KLOW research page lists five PubMed records and no study of the filled blend.[6](#src-6) This page uses that list and does not add a longer review. The journal plate on each study is drawn for this page. It names the real journal and year. It is not the publisher’s cover.

Study authors are credited for their papers. They did not write, review, or endorse this site. Where a paper uses therapeutic language, that language is the authors’ statement about the single molecule they studied. This site does not adopt it as a statement about KLOW.

## KPV _papers._

Two papers about the Lys-Pro-Val tripeptide. Neither puts that tripeptide in a solution with BPC-157, TB-500, and GHK-Cu.

*Diagram: Journal plate for Gastroenterology, 2008. Drawn for this page, not the publisher cover.*

01 · KPV · Cells and two mouse models

### The tripeptide, studied on its own

G. Dalmasso, L. Charrier-Hisamuddin, H. T. T. Nguyen, Y. Yan, S. Sitaraman, and D. Merlin, 2008

A paper about KPV. Not a paper about KLOW.

[1](#src-1) The authors studied whether the Lys-Pro-Val tripeptide enters intestinal epithelial cells and immune cells through the PepT1 transporter, and what they observed in two mouse colitis models. They discuss KPV as a candidate in that line of research. That discussion is about KPV alone. It is not a controlled human trial, and it is not a test of this pen or vial.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. _Gastroenterology_. 2008;134(1):166–178. [PMID 18061177](https://pubmed.ncbi.nlm.nih.gov/18061177/) [doi:10.1053/j.gastro.2007.10.026](https://doi.org/10.1053/j.gastro.2007.10.026)

*Diagram: Journal plate for the Journal of Pharmacology and Experimental Therapeutics, 2003. Drawn for this page, not the publisher cover.*

02 · KPV · Compared with other MSH pieces

### The C-terminal tripeptide, in mice

S. J. Getting, H. B. Schiöth, and M. Perretti, 2003

A comparison of KPV with other fragments of alpha-MSH. Not a test of the blend.

[2](#src-2) The authors identify KPV as the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. In a mouse peritonitis model they report that KPV reduced the accumulation of neutrophils, and that this effect did not match the effect of the core melanocortin peptides. The experiment compares those fragments. It does not include BPC-157, TB-500, or GHK-Cu, and it is not a human trial of KLOW.

Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. _J Pharmacol Exp Ther_. 2003;306(2):631–637. [PMID 12750433](https://pubmed.ncbi.nlm.nih.gov/12750433/) [doi:10.1124/jpet.103.051623](https://doi.org/10.1124/jpet.103.051623)

## The BPC-157 _paper._

A review of animal wound models of the 15-amino-acid peptide, from the laboratory that produced much of that work.

*Diagram: Journal plate for Frontiers in Pharmacology, 2021. Drawn for this page, not the publisher cover.*

03 · BPC-157 · Review from Zagreb

### Animal wound models of one peptide

S. Seiwerth, M. Milavic, J. Vukojevic, and colleagues, 2021

A review of BPC-157. Not a review of KLOW.

[3](#src-3) Seiwerth and colleagues review animal wound models of BPC-157, the synthetic 15-amino-acid peptide. The review comes from the University of Zagreb group that produced much of that literature. It discusses BPC-157 on its own. It is not a controlled human trial, and it is not a study of a solution that also contains KPV, a thymosin fragment, and GHK-Cu. This site does not carry the review’s therapeutic wording over to the blend. BPC-157’s own U.S. record is on [bpc157pens.com](https://bpc157pens.com/bpc-157-legal-status/).

Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. _Front Pharmacol_. 2021;12:627533. [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/) [doi:10.3389/fphar.2021.627533](https://doi.org/10.3389/fphar.2021.627533)

## The GHK _paper._

A review of the tripeptide and its copper complex. Not a review of the four-peptide product.

*Diagram: Journal plate for the Journal of Biomaterials Science, Polymer Edition, 2008. Drawn for this page, not the publisher cover.*

04 · GHK-Cu · Review

### The copper complex, by itself

L. Pickart, 2008

About glycyl-L-histidyl-L-lysine and GHK-Cu. Not about KLOW.

[4](#src-4) Pickart reviews the tripeptide GHK and the copper complex it forms, GHK-Cu. The paper summarizes laboratory observations and some human observations the author attributes to that complex, including tissue-remodeling work. Those statements are about GHK and GHK-Cu. They are not evidence about a blend that also contains KPV, BPC-157, and a thymosin fragment, and they are not a study of this pen or vial.

Pickart L. The human tri-peptide GHK and tissue remodeling. _J Biomater Sci Polym Ed_. 2008;19(8):969–988. [PMID 18644225](https://pubmed.ncbi.nlm.nih.gov/18644225/) [doi:10.1163/156856208784909435](https://doi.org/10.1163/156856208784909435)

## The thymosin beta-4 _paper._

A review of the longer peptide, thymosin beta-4. The KLOW certificate names a 17–23 fragment. This paper is not a test of that fragment in this pen.

*Diagram: Journal plate for Expert Opinion on Biological Therapy, 2012. Drawn for this page, not the publisher cover.*

05 · Thymosin β4 · Review

### The parent peptide, not the named fragment

A. L. Goldstein, E. Hannappel, G. Sosne, and H. K. Kleinman, 2012

About thymosin beta-4. Not about the KLOW blend, and not a test of the 17–23 fragment as sold in this pen.

[5](#src-5) The authors review thymosin beta-4, a longer peptide that binds actin, and they discuss proposed clinical uses of that molecule. The seller describes TB-500 on the KLOW label as a synthetic actin-binding fragment of thymosin beta-4. The pen certificate names the analyte “TB500 (17–23 Fragment).” This paper is about the longer peptide. It does not test that fragment as filled in the KLOW pen or vial, and it does not test the four-peptide solution.

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. _Expert Opin Biol Ther_. 2012;12(1):37–51. [PMID 22074294](https://pubmed.ncbi.nlm.nih.gov/22074294/) [doi:10.1517/14712598.2012.634793](https://doi.org/10.1517/14712598.2012.634793)

## Sources

The five papers are the seller’s list. The descriptions above are from the papers. The authors did not write, review, or endorse this site.

1.  Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. _Gastroenterology_. 2008;134(1):166–178. [PMID 18061177](https://pubmed.ncbi.nlm.nih.gov/18061177/)
2.  Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. _J Pharmacol Exp Ther_. 2003;306(2):631–637. [PMID 12750433](https://pubmed.ncbi.nlm.nih.gov/12750433/)
3.  Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. _Front Pharmacol_. 2021;12:627533. [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/)
4.  Pickart L. The human tri-peptide GHK and tissue remodeling. _J Biomater Sci Polym Ed_. 2008;19(8):969–988. [PMID 18644225](https://pubmed.ncbi.nlm.nih.gov/18644225/)
5.  Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. _Expert Opin Biol Ther_. 2012;12(1):37–51. [PMID 22074294](https://pubmed.ncbi.nlm.nih.gov/22074294/)
6.  Palm Beach Vitality. KLOW research page, the five-paper reading list, checked November 18, 2026. [palmbeach-vitality.store](https://palmbeach-vitality.store/research/klow/?utm_source=klowpens&utm_medium=referral&utm_campaign=site&utm_content=ref_reading_list)
